GDS Wealth Management trimmed its UnitedHealth Group holding by 10.7% during the most recent quarter, disposing of 5,297 shares and reducing its position to 44,252 shares worth approximately $15.28 million at the end of the period. This sale marks one of the larger single-quarter reductions among top institutional holders, reflecting a recalibration of allocation to the healthcare sector.

Several smaller advisory firms initiated or adjusted positions in UnitedHealth Group during the same reporting window. LFA Lugano Financial Advisors established a new position valued at $25,000, Sagard Holdings added $29,000, Grey Fox Wealth Advisors invested $33,000, and Islay Capital Management committed $31,000. Meanwhile, Riggs Asset Management grew its stake by 69.4%, acquiring an additional 43 shares to reach 105 shares valued at $33,000. Collectively, hedge funds and institutional investors now account for 87.86% of outstanding shares.

Wall Street analysts remain broadly positive on UnitedHealth Group’s outlook. Jefferies boosted its target by 29% to $409 and maintains a Buy rating, while Goldman Sachs initiated coverage with a $406 objective and a Buy recommendation. UBS raised its target to $430, Piper Sandler set an Overweight rating with a $417 goal, and Mizuho reiterated an Outperform stance with a $430 target. Of the 29 analysts covering the stock, 17 rate it Buy, nine Hold and two Sell, supporting a consensus Moderate Buy rating and an average target near $386.

In its latest quarterly report, UnitedHealth Group delivered revenue of $113.16 billion, up 12.2% year-over-year, and reported earnings per share of $2.92, beating consensus by $0.05. Net margin stood at 4.04% and return on equity at 19.23%. The company announced a quarterly dividend of $2.21 per share—an annualized yield of 2.5%—with a payout ratio of 46.14%, reflecting continued commitment to returning capital to shareholders.